Antiangiogenic photodynamic therapy (PDT) using Visudyne causes effective suppression of tumor growth

Cancer Letters

Volumn 205, Issue 1, 2004, Pages 39-48

  Ichikawa, Kanae ^a   Takeuchi, Yoshito ^a   Yonezawa, Sei ^a   Hikita, Tomoya ^a   Kurohane, Kohta ^a   Namba, Yukihiro ^b   Oku, Naoto ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b Nippon Fine Chemical Co Ltd   (Japan)

Author keywords

Angiogenesis; Benzoporphyrin derivative monoacid ring A; Liposome; Photodynamic therapy; Visudyne

Indexed keywords

BENZOPORPHYRIN DERIVATIVE; CHOLESTEROL; DIMYRISTOYLPHOSPHATIDYLCHOLINE; DIPALMITOYLPHOSPHATIDYLCHOLINE; DIPALMITOYLPHOSPHATIDYLGLYCEROL; LIPID; LIPOPROTEIN; LIPOSOME; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLGLYCEROL; PHOTOSENSITIZING AGENT;

AIR SAC; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD FLOW; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER THERAPY; CELL LINE; COLUMN CHROMATOGRAPHY; CONTROLLED STUDY; DRUG FORMULATION; EGG YOLK; ENDOTHELIUM CELL; EXPERIMENTAL MODEL; EXPERIMENTAL MOUSE; HEMOSTASIS; HUMAN; HUMAN CELL; LASER; LIQUID; MALE; MOUSE; NONHUMAN; PHOTODYNAMIC THERAPY; PHOTOTOXICITY; PRIORITY JOURNAL; SARCOMA; SERUM; TUMOR GROWTH;

EID: 1242271222     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2003.10.001     Document Type: Article

References (29)

1. Dolmans D.E., Fukumura D., Jain R.K. Photodynamic therapy for cancer. Nat. Rev. Cancer. 2003;380-387.
2. Peng Q., Warloe T., Moan J., Godal A., Apricena F., Giercksky K.E., Nesland J.M. Antitumor effect of 5-aminolevulinic acid-mediated photodynamic therapy can be enhanced by the use of a low dose of photofrin in human tumor xenografts. Cancer Res. 61:2001;5824-5832.
3. Reuther T., Kubler A.C., Zillmann U., Flechtenmacher C., Sinn H. Comparison of the in vivo efficiency of photofrin II-, mTHPC-, mTHPC-PEG- and mTHPCnPEG-mediated PDT in a human xenografted head and neck carcinoma. Lasers Surg. Med. 29:2001;314-322.
4. Dougherty T.J., Gomer C.J., Henderson B.W., Jori G., Kessel D., Korbelik M., Moan J., Peng Q. Photodynamic therapy. J. Natl Cancer Inst. 90:1998;889-905.
5. Vicente M.G. Porphyrin-based sensitizers in the detection and treatment of cancer: recent progress. Curr. Med. Chem. Anti-Cancer Agents. 1:2001;175-194.
6. Pushpan S.K., Venkatraman S., Anand V.G., Sankar J., Parmeswaran D., Ganesan S., Chandrashekar T.K. Porphyrins in photodynamic therapy - a search for ideal photosensitizers. Curr. Med. Chem. Anti-Cancer Agents. 2:2002;187-207.
7. Engbrecht B.W., Menon C., Kachur A.V., Hahn S.M., Fraker D.L. Photofrin-mediated photodynamic therapy induces vascular occlusion and apoptosis in a human sarcoma xenograft model. Cancer Res. 59:1999;4334-4342.
8. Waterfield E.M., Renke M.E., Smits C.B., Gervais M.D., Bower R.D., Stonefield M.S., Levy J.G. Wavelength-dependent effects of benzoporphyrin derivative monoacid ring A in vivo and in vitro. Photochem. Photobiol. 60:1994;383-387.
9. Obochi M.O., Canaan A.J., Jain A.K., Richter A.M., Levy J.G. Targeting activated lymphocytes with photodynamic therapy: susceptibility of mitogen-stimulated splenic lymphocytes to benzoporphyrin derivative (BPD) photosensitization. Photochem. Photobiol. 62:1995;169-175.
10. Ciulla T.A., Danis R.P., Criswell M., et al. Changing therapeutic paradigms for exudative age-related macular degeneration: antiangiogenic agents and photodynamic therapy. Expert. Opin. Investig. Drugs. 8:1999;2173-2182.
11. Richter A.M., Waterfield E., Jain A.K., Canaan A.J., Allison B.A., Levy J.G. Photodynamic. Ther. Biomed. Lasers. 1992;549.
12. Kurohane K., Tominaga A., Sato S., North J.R., Namba Y., Oku N. Photodynamic therapy targeted to tumor-induced angiogenic vessels. Cancer Lett. 167:2001;49-56.
13. Oku N., Saito N., Namba Y., Tsukada H., Dolphin D., Okada S. Application of long-circulating liposomes to cancer photodynamic therapy. Biol. Pharm. Bull. 20:1997;670-673.
14. Chonn A., Semple S.C., Cullis P.R. Separation of large unilamellar liposomes from blood components by a spin column procedure: towards identifying plasma proteins which mediate liposome clearance in vivo. Biochimica Biophysica Acta. 1070:1991;215-222.
15. Oku N., Tokudome Y., Namba Y., Saito N., Endo M., Hasegawa Y., et al. Effect of serum protein binding on real-time trafficking of liposomes with different charges analyzed by positron emission tomography. Biochimca Biophysica Acta. 1280:1996;149-154.
16. Chonn A., Semple S.C., Cullis P.R. Association of blood proteins with large unilamellar liposomes in vivo. Relation to circulation lifetimes. J. Biol. Chem. 267:1992;18759-18765.
17. Takeuchi Y., Kurohane K., Ichikawa K., Yonezawa S., Nango M., Oku N. Induction of intensive tumor suppression by anti-angiogenic photodynamic therapy using polycation-modified liposomal photosensitizer. Cancer. 97:2003;2027-2034.
18. Asai T., Shimizu K., Kondo M., Kuromi K., Watanabe K., Ogino K., et al. Anti-neovascular therapy by liposomal DPP-CNDAC targeted to angiogenic vessels. Fed. Eur. Biochem. Soc. Lett. 520:2002;167-170.
19. Oku N., Asai T., Watanabe K., Kuromi K., Nagatsuka M., Kurohane K., Kikkawa H., et al. Anti-neovascular therapy using novel peptides homing to angiogenic vessels. Oncogene. 21:2002;2662-2669.
20. Oku N., Doi K., Namba Y., Okada S. Therapeutic effect of adriamycin encapsulated in long-circulating liposomes on Meth-A-sarcoma-bearing mice. Int. J. Cancer. 58:1994;415-419.
21. Annna A.M., Jain A.K., Canaan A.J., Waterfield E., Sterivberg E.D., Levy J.G. Photosensitizing efficiency of two regioisomers of the benzoporphyrin derivative monoacid ring A (BPD-MA). Biochem. Pharmacol. 43:1992;2349-2358.
22. Momma T., Hamblin M.R., Wu H.C., Hasan T. Photodynamic therapy of orthotopic prostate cancer with benzoporphyrin derivative: local control and distant metastasis. Cancer Res. 58:1998;5425-5431.
23. Busetti A., Soncin M., Jori G., Rodgers M.A.J. High efficiency of benzoporphyrin derivative in the photodynamic therapy of pigmented malignant melanoma. Br. J. Cancer. 79:1999;821-824.
24. Trauner K.B., Gandour-Edwards R., Bamberg M., Shortkroff S., Sledge C., Hasan T. Photodynamic synovectomy using benzoporphyrin derivative in an antigen-induced arthritis model for rheumatoid arthritis. Photochem. Photobiol. 67:1998;133-139.
25. Richter A.M., Waterfield E., Jain A.K., Canaan A.J., Allison B.A., Levy J.G. Liposomal delivery of a photosensitizer, benzoporphyrin derivative monoacid ring A (BPD), to tumor tissue in a mouse tumor model. Photochem. Photobiol. 57:1993;1000-1006.
26. Fingar V.H., Kik P.K., Haydon P.S., Cerrito P.B., Tseng M., Abang E., Wieman T.J. Analysis of acute vascular damage after photodynamic therapy using benzoporphyrin derivative (BPD). Br. J. Cancer. 79:1999;1702-1708.
27. Dolmans D.E., Kadambi A., Hill J.S., Flores K.R., Gerber J.N., Walker J.P., et al. Targeting tumor vasculature and cancer cells in orthotopic breast tumor by fractionated photosensitizer dosing photodynamic therapy. Cancer Res. 62:2002;4289-4294.
28. Pogue B.W., O'Hara J.A., Demidenko E., Wilmot C.M., Goodwin I.A., Chen B., Swartz H.M., Hasan T. Photodynamic therapy with verteporfin in the radiation-induced fibrosarcoma-1 tumor causes enhanced radiation sensitivity. Cancer Res. 63:2003;1025-1033.
29. Dolmans D.E., Kadambi A., Hill J.S., Waters C.A., Robinson B.C., Walker J.P., Fukumura D., Jain R.K. Vascular accumulation of a novel photosensitizer, MV6401, causes selective thrombosis in tumor vessels after photodynamic therapy. Cancer Res. 62:2002;2151-2156.